Table 3.
SLPI measured at different time points. Serum and urinary SLPI concentrations quantified by ELISA and compared between patients with and without AKI. Bold fonts indicate p-values <0.05.
| Serum SLPI | ||||||||||
| SLPI (ng/mL) | Development Cohort (n = 60) | Validation Cohort (n = 148) | ||||||||
| No AKI | AKI | p-Value | No AKI | AKI | p-Value | |||||
| (n = 46) | (n = 14) | (n = 226) | (n = 22) | |||||||
| Pre-OP | 67.3 | (57.2–82.1) | 87.6 | (65.3–98.5) | 0.14 | 40.1 | (31.6 –48.5) | 43.7 | (36.6–52.4) | 0.280 |
| 0 h after surgery | 66.3 | (52.8–81.15) | 102.7 | (83.2–128.2) | 0.06 | 29.7 | (22.4–39.9) | 37.9 | (25.4–45.3) | 0.127 |
| 6 h after surgery | 64.9 | (53.9–84.7) | 102.1 | (93.2–131.5) | <0.001 | |||||
| 12 h after surgery | 74.7 | (52.0–88.1) | 114.5 | (95.0–134.5) | <0.001 | |||||
| 24 h after surgery | 86.1 | (69.0–113.5) | 117.9 | (105.6–145.2) | 0.001 | 80.4 | (64.7–111.7) | 106.6 | (83.0–135.3) | 0.008 |
| 48 h after surgery | 58.5 | (58.5–90.0) | 98.8 | (76.0–110.4) | 0.000 | |||||
| Urinary SLPI | ||||||||||
| SLPI (ng/mL) | Development Cohort (n = 60) | Validation Cohort (n = 148) | ||||||||
| No AKI | AKI | p-Value | No AKI | AKI | p-Value | |||||
| (n = 46) | (n = 14) | (n = 226) | (n = 22) | |||||||
| Pre-OP | 1.10 | (0.40–2.09) | 0.40 | (0.17–0.96) | 0.022 | 0.51 | (0.15–1.53) | 0.8 | (0.20–1.36) | 0.520 |
| 0 h after surgery | 0.23 | (0.07–1.09) | 0.58 | (0.31–2.02) | 0.056 | 0.13 | (0.025–0.35) | 0.98 | (0.98–1.40) | 0.073 |
| 24 h after surgery | 2.20 | (0.74–5.05) | 2.38 | (0.33–9.23) | 0.942 | 1.15 | (0.71–1.92) | 1.08 | (0.90–1.62) | 0.575 |
Patients with AKI showed significantly elevated serum SLPI after surgery. AKI, acute kidney injury; Pre-OP, before surgery; SLPI, secretory leukocyte protease inhibitor. Data are reported as median (Q1–Q3). p-values were analyzed using the Mann–Whitney U test.